Comparing Quoin Pharmaceuticals (NASDAQ:QNRX) & Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evoke Pharma and Quoin Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evoke Pharma	0	0	0	0	N/A
Quoin Pharmaceuticals	0	0	1	0	3.00

Quoin Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 550.94%. Given Quoin Pharmaceuticals’ higher possible upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Evoke Pharma.

Institutional and Insider Ownership

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 6.1% of Evoke Pharma shares are owned by insiders. Comparatively, 3.3% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Evoke Pharma and Quoin Pharmaceuticals’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evoke Pharma	$5.18 million	0.83	-$7.79 million	($1.83)	-0.27
Quoin Pharmaceuticals	N/A	N/A	-$8.69 million	($7.27)	-0.08

Evoke Pharma has higher revenue and earnings than Quoin Pharmaceuticals. Evoke Pharma is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Evoke Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Evoke Pharma and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evoke Pharma	-116.75%	-4,908.09%	-78.43%
Quoin Pharmaceuticals	N/A	-107.57%	-56.01%

Summary

Quoin Pharmaceuticals beats Evoke Pharma on 7 of the 11 factors compared between the two stocks.

About Evoke Pharma

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.